Moon­Lake out­lines more da­ta in pso­ri­at­ic arthri­tis as it preps for piv­otal tri­als: #AAD24

Moon­Lake Im­munother­a­peu­tics on Sun­day tout­ed up­dat­ed da­ta from a Phase II pso­ri­at­ic arthri­tis tri­al that­was met with skep­ti­cism last year, and has now out­lined its Phase III path for­ward.

Af­ter 24 weeks, 61% of pa­tients tak­ing the 60 mg dose of sonelokimab saw at least a 50% re­duc­tion in swollen and ten­der joints, while 58% tak­ing the 120 mg dose re­spond­ed to that lev­el. Those fig­ures fell in range of an­a­lyst ex­pec­ta­tions, with TD Cowen’s Phil Nadeau es­ti­mat­ing about a 60% re­sponse rate on this mea­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER